IN2013MN01394A - - Google Patents

Download PDF

Info

Publication number
IN2013MN01394A
IN2013MN01394A IN1394MUN2013A IN2013MN01394A IN 2013MN01394 A IN2013MN01394 A IN 2013MN01394A IN 1394MUN2013 A IN1394MUN2013 A IN 1394MUN2013A IN 2013MN01394 A IN2013MN01394 A IN 2013MN01394A
Authority
IN
India
Prior art keywords
alphabodies
polypeptides
nucleic acids
host cells
compositions
Prior art date
Application number
Inventor
Ignace Lasters
Johan Desmet
Maria Henderikx
Anita Wehnert
Geert Meersseman
Original Assignee
Complix Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Complix Nv filed Critical Complix Nv
Publication of IN2013MN01394A publication Critical patent/IN2013MN01394A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Abstract

Alphabodies that specifically bind to cytokines or growth factor and/or their receptors as well as polypeptides that comprise or essentially consist of such Alphabodies. Further nucleic acids encoding such Alphabodies; methods for preparing such Alphabodies and polypeptides; host cells expressing or capable of expressing such Alphabodies and polypeptides; compositions and in particular pharmaceutical compositions that comprise such Alphabodies polypeptides nucleic acids and/or host cells; and uses of such Alphabodies or polypeptides nucleic acids host cells and/or compositions in particular for prophylactic therapeutic or diagnostic purposes.
IN1394MUN2013 2011-01-06 2012-01-06 IN2013MN01394A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011050138 2011-01-06
PCT/EP2012/050193 WO2012093172A1 (en) 2011-01-06 2012-01-06 Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors

Publications (1)

Publication Number Publication Date
IN2013MN01394A true IN2013MN01394A (en) 2015-06-12

Family

ID=44242740

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1394MUN2013 IN2013MN01394A (en) 2011-01-06 2012-01-06

Country Status (9)

Country Link
US (1) US20140057830A1 (en)
JP (1) JP2014504869A (en)
CN (1) CN103339148A (en)
AU (1) AU2012204846B2 (en)
BR (1) BR112013017367A2 (en)
CA (1) CA2821646A1 (en)
DK (1) DK2661447T3 (en)
IN (1) IN2013MN01394A (en)
WO (1) WO2012093172A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
AU2013207209B2 (en) * 2012-01-06 2017-02-16 Complix Nv Binding agents to intracellular target molecules
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2014064080A1 (en) 2012-10-22 2014-05-01 Complix Nv Polypeptides specifically binding to il-23
EP2909233B1 (en) 2012-10-22 2016-12-07 Complix NV Polypeptides capable of cellular internalization
JP6768639B2 (en) 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド Treatment of eosinophil or mast cell related disorders
WO2017102835A1 (en) * 2015-12-14 2017-06-22 Complix Nv Binding molecule comprising an alphabody-polypeptide and an antibody
CN113315431B (en) * 2021-04-22 2023-07-28 湖南工业大学 PMSM loss-of-magnetic fault control method based on equivalent input interference system and motor
CN114544812B (en) * 2022-02-18 2023-06-30 复旦大学附属中山医院 Application of metabolic combination type marker in diagnosis of asthma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101323643B (en) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 Optimized TACI-Fc fuse protein
EP2161278B1 (en) * 2008-09-08 2012-05-23 Complix N.V. Single-chain coiled coil scaffold
CA2749558C (en) * 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
WO2012092970A1 (en) * 2011-01-06 2012-07-12 Complix Nv Alphabody libraries and methods for producing the same

Also Published As

Publication number Publication date
AU2012204846B2 (en) 2016-09-08
US20140057830A1 (en) 2014-02-27
WO2012093172A1 (en) 2012-07-12
AU2012204846A1 (en) 2013-07-04
JP2014504869A (en) 2014-02-27
CN103339148A (en) 2013-10-02
BR112013017367A2 (en) 2016-11-22
CA2821646A1 (en) 2012-07-12
DK2661447T3 (en) 2015-11-02

Similar Documents

Publication Publication Date Title
IN2013MN01394A (en)
EA201290567A1 (en) PREPARATION OF HETEROLOGICAL POLYPEPTIDES IN MICROWATEREDES, EXTRA-CELLED MICROWAVE-ALONG CALVES, COMPOSITIONS AND METHODS OF THEIR RECEIVING AND APPLICATION
PH12014501912A1 (en) Cx3cr1-binding polypeptides
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
TN2014000438A1 (en) Anti-fcrn antibodies
MX346923B (en) Genes and proteins for alkanoyl-coa synthesis.
ZA201400490B (en) Arginine- free tnfr: fc- fusion polypeptide compositions and methods of use
IN2014MN01562A (en)
MX2015007921A (en) Novel heterocyclic compounds as bromodomain inhibitors.
MX2012011771A (en) Aptamers to î²-ngf and their use in treating î²-ngf mediated diseases and disorders.
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
MY162737A (en) 4-1bb binding molecules
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
IN2015DN03322A (en)
PH12014501970A1 (en) Antibodies to bradykinin b1 receptor ligands
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
EP2855503A4 (en) Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
MX366178B (en) Human btnl3 proteins, nucleic acids, and antibodies and uses thereof.
EP2744480A4 (en) Low protein percentage gelling compositions
MX2013003859A (en) Picropodophyllin polymorphs b or c for use in cancer therapy.
MX2014010958A (en) Activated immunostimulatory cell composition and uses thereof.
AU2011301714A8 (en) Synthetic gene for expressing Sm-14 in Pichia pastoris, methods for producing and purifying Sm-14 and the use thereof as a vaccine and diagnostic medium
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands